A Phase II Study of the safety, tolerability and antitumor activity of tucatinib in combination with eribulin and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Elena Shagisultanova

Elena Shagisultanova

Study ID

Protocol Number: 22-1407

More information available at ClinicalTrials.gov: NCT05458674

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers